Unpacking A 97.60% Potential Upside In The Biotech Arena
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is catching the attention of investors with its promising pipeline of monoclonal antibody therapeutics targeting inflammatory and immunology (I&I) diseases. Headquartered in Menlo Park, California, this clinical-stage biopharmaceutical company is making significant strides in the biotechnology sector, particularly with innovative treatments for psoriasis (PsO) and psoriatic arthritis.
The company, boasting a market cap of $1.28 billion, has seen its stock fluctuate within a 52-week range of $6.78 to $32.12, currently trading at $26.40. Despite a marginal dip of 0.05% in recent trading, Oruka’s share price is backed by substantial analyst confidence, highlighting a potential upside of…
